J07BK01 • live attenuated chickenpox vaccine • Antiinfectives for systemic use | Viral vaccines | Varicella zoster vaccines
The live attenuated varicella vaccine is used to prevent chickenpox, a highly contagious viral disease caused by the varicella-zoster virus (VZV). The vaccine contains a weakened form of the virus, which stimulates the immune system to produce antibodies against VZV, providing long-term protection against infection.
The vaccine is administered subcutaneously, usually in two doses, with the first dose given at 12-15 months of age and the second between 4 and 6 years. It is recommended for both children and adults who have not had chickenpox or been previously vaccinated.
Common side effects include redness, pain, or swelling at the injection site, mild fever, and rashes. In rare cases, severe allergic reactions or neurological complications may occur.
The live attenuated varicella vaccine is an effective preventive measure, helping to reduce the incidence of chickenpox and its associated complications, such as secondary bacterial infections and viral pneumonia.
Substance: live attenuated chickenpox vaccine
Date of last drug list: 01-07-2013
Commercial code: W13412018
Concentration: 10^3.3 PFU / 0.5ml
Pharmaceutical form: lyophilizate + solvent for injection
Quantity: 100
Product type: generic
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).